<SEC-DOCUMENT>0001121404-24-000011.txt : 20240425
<SEC-HEADER>0001121404-24-000011.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240425104931
ACCESSION NUMBER:		0001121404-24-000011
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		24873696

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6kcoverpagepressreleaseq1.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8aea1300b4c04569b34b26cd63b1e212_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of April 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#58;&#160;001-31368</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANOFI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46, avenue de la Grande Arm&#233;e, 75017 Paris, FRANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Press release dated April 25, 2024&#58; Sanofi Q1&#58; robust 7% sales growth driven by launches, underpins full-year guidance</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.635%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 25, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Legal Corporate &#38; Finance</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseq12024english.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_1"></div><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Press Release                                                              </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><img alt="image.jpg" src="image.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"></div><div style="padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:14pt;font-style:italic;font-weight:400;line-height:112%">Sanofi Q1&#58; robust 7% sales growth driven by launches, underpins full-year guidance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Paris, April 25, 2024</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales growth of 6.7% at CER and business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> of </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;1.78</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Dupixent sales up 24.9% to &#8364;2,835 million, on target to deliver &#126;&#8364;13bn in 2024</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Pharma launches up 90.5% to &#8364;606 million, led by Nexviazyme and ALTUVIIIO</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Vaccines sales up 5.6%, boosted by Beyfortus</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Consumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performance</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">R&#38;D expenses gre</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w 11.8%</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reflecting strategic shift of resources into development</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">SG&#38;A expenses gr</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ew 2.9%,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> less than sales growth</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of &#8364;1.78</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, dow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n 17.6%</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reported and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4%</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at CER</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">IFRS EPS of &#8364;0.91, down 43.1% reported</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D transformation advanced further</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Three regulatory approvals&#58; new Dupixent indications in the US and Japan and Beyfortus in Japan</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Positive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare disease</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Reaffirming increasing pipeline news flow over 2024-2025, including 12 phase 3 data readouts</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Social Responsibility progress</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Sanofi Global Health Unit&#58; making a difference for patients in low- and middle-income countries</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Cancer and work&#58; Sanofi supporting health and wellbeing in the workplace</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business EPS guidance reiterated</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Sanofi expects 2024 business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average April 2024 exchange rates, the currency impact on 2024 business EPS is estimated between</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -5.5% to -6.5%.<br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Paul Hudson, Chief Executive Officer, commented&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">&#8220;We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024.&#8221;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_4"></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net sales reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;10,464m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+2.4%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.7%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net income reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1,133m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-43.2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS EPS reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;0.91</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-43.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;(309)m</font></td><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-120.1%</font></td><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2,843m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-14.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-4.2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2,219m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-17.8%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-7.4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1.78</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-17.6%</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-7.4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 7). The consolidated income statement for Q1 2024 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4&#59; (2) 2023 business EPS was &#8364;8.11&#59; (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 7).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  1                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_7"></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Q1 2024 summary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">----------------------------</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The performance shown in this press release covers the three-month period to 31 March 2024 (the quarter or Q1 2024) compared to the three-month period to 31 March 2023 (Q1 2023) respectively and all percentage changes in sales in this press release are at CER</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, unless stated otherwise.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">---------------------</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Q1 2024, on a reported basis, Sanofi sales were &#8364;10,464 million, an increase of 2.4%. Exchange rate movements had a negative effect of 4.3 percentage points (pp). At CER, sales increased by 6.7%.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Sales breakdown</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">% of</font></div><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#160;total sales</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,939</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.3&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.4&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;Pharma</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">7,762</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">74.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;Vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">1,177</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CHC</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,525</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+9.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Sales</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,464</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+6.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Business operating income (BOI) decreased by 14.7% to &#8364;2,843 million. At CER, BOI decreased by 4.2%. The ratio of BOI to net sales decreased 5.4pp to 27.2% (down 3.3pp to 29.3% at CER).</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Acquisitions and major collaborations</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 23, Sanofi and Inhibrx, Inc., entered into an agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for $30.0 in cash, a contingent value right of $5.0 and 0.25 shares of a new publicly traded company that will retain Inhibrx&#8217;s non-INBRX-101 assets. INBRX-101 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency patients to achieve normalization of serum AAT levels with less frequent dosing. The acquisition supports Sanofi&#8217;s strategy and complements 30-years of heritage in rare diseases and proven industry leadership in immunology and inflammation. This acquisition is subject to customary closing conditions and is expected to close in Q2 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_10"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Sales by geographic region</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,316</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+7.3&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,480</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-4.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of World</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,668</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;of which China</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">757&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.2&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">US </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales increased by 7.3% to &#8364;4,316 million. The strong performance of Dupixent as well as the Pharma launches and Beyfortus late-season deliveries were partially offset by the impact of generic competition on Aubagio as well as lower sales of Lantus.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Europe</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales decreased by 4.0% to &#8364;2,480 million reflecting the impact of generic competition on Aubagio, lower sales of Lovenox and a high base of comparison for Vaccines due to COVID-19 vaccine sales recorded in Q1 2023 which more than offset the strong performance of Dupixent.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rest of World </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sales increased by 13.8% to &#8364;3,668 million, mainly driven by Dupixent, Beyfortus launch in two Southern Hemisphere countries and CHC. Sales in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">China</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> increased by 6.2% to &#8364;757 million driven by Dupixent, Toujeo and Plavix.<br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">See Appendix 9 for definitions of financial indicators.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  2                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_13"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:15pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Biopharma</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Biopharma segment includes </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pharma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Sales increased by 6.3% to &#8364;8,939 million, driven by continued strong performance of Dupixent, Pharma launches and Vaccines. The divestments of medicines&#47;portfolio streamlining had a negative impact of 0.7pp.<br></font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Pharma</font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_260"></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dupixent</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dupixent</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,835&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+24.9&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (collaboration with Regeneron) sales increased by 24.9% to 2,835 million. In the US, in-market performance was strong with total prescriptions up by 25% (year-over-year) and new-to-brand prescriptions up by 22%, impacted by the customary dynamics of the annual reset of insurance plans. Sales increased by 16.8% to &#8364;2,030 million and were driven by continued strong demand in the approved indications&#58; atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis. In Europe, Dupixent sales increased by 33.6% to &#8364;371 million reflecting continued growth in AD, asthma and CRSwNP. In the Rest of World region, sales reached &#8364;434 million, an increase of 67.5%, driven mainly by sales in Japan and China.</font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_16"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Pharma launches</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+96.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALTUVIIIO</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sarclisa</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+28.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Rezurock</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+40.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cablivi</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xenpozyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enjaymo</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+87.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">TZIELD</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Pharma launches</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">606</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+90.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Nexviazyme&#47;Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> sales were &#8364;152 million, including &#8364;85 million in the US, and increased by 96.3% driven by the conversion from Myozyme&#47;Lumizyme in the eligible late-onset Pompe disease population and by new patients. Pompe franchise (Nexviazyme&#47;Nexviadyme + Myozyme&#47;Lumizyme) sales were at &#8364;343 million, an increase of 15.2%. Nexviazyme&#47;Nexviadyme sales now represent 44% of the Pompe franchise.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (hemophilia A) was launched at the end of March 2023 and generated sales of &#8364;122 million, mainly in the US where ALTUVIIIO growth was driven by patient switches, the majority coming from medicines other than Eloctate. The hemophilia A franchise (ALTUVIIIO + Eloctate) sales were &#8364;208 million and increased b</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">y 79.0%, i</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mproving Sanofi&#8217;s share in the factor and the overall hemophilia A market.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (multiple myeloma) sales were &#8364;106 million, an increase of 28.7%, driven by strong growth in the US and the Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rezurock</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (chronic graft-versus-host disease) sales were &#8364;93 million, an increase of 40.3%, driven by improved patient adherence and new patients in the US as well as launches in China and UK.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cablivi</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (acquired thrombotic thrombocytopenic purpura) sales increased by 3.4% to &#8364;59 million, primarily driven by use in the US.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Xenpozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (acid sphingomyelinase deficiency) sales were &#8364;35 million, an increase of 100.0%, driven by use in the US and Europe.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enjaymo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (cold agglutinin disease) sales were &#8364;29 million, mainly generated in the US and Japan.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TZIELD</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (delay onset of type 1 diabetes) sales were &#8364;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> million driven by increased screenings and infusions. The launch continues to be supported&#8239;by targeted investments, improved awareness and availability of guidelines.<br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  3                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_19"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:15pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other main medicines</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-15.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Toujeo</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+18.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lovenox</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-13.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Fabrazyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plavix</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cerezyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+23.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Myozyme&#47;Lumizyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Alprolix</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Praluent</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+25.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thymoglobulin</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+12.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Aubagio</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-74.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-24.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+15.1&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;360 million, a decrease of 15.4%. In the US, sales decreased by 13.6% to &#8364;112 million, reflecting a high comparison in Q1 2023 ahead of an adjustment to reflect increasing sales to government customers. These developments more than offset an increase in volume due to a competitor medicine withdrawing from the US market. In China, sales decreased by 52.5% million to &#8364;27 million as patients are shifting to Toujeo.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Toujeo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased by 18.0% to &#8364;321 million driven by China where the market share now exceeds that of Lantus. In the US, sales decreased mainly due to a shift in sales channel mix, resulting in a lower average net price, more than offsetting an increase in volume and market share.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lovenox</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales decreased by 13.9% to &#8364;262 million, reflecting an impact from volume-based procurement in China as well as biosimilar competition, which was largely offset by growth in some other countries.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Fabrazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> sales increased by 7.7% to &#8364;253 million, driven by the Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Plavix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales increased by 6.8% to &#8364;238 million driven by use in China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cerezyme </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sales increased by 23.0% to &#8364;214 million, reflecting growth in high-inflation countries (Argentina and Turkey), part of the Rest of World. Gaucher disease franchise (Cerezyme + Cerdelga) sales wer</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e &#8364;297 million, an increase of 20.8%.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales decreased by 13.6% to &#8364;191 million reflecting the conversion to Nexviazyme&#47;Nexviadyme mentioned above.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Alprolix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;130 million, an increase of 6.4%, driven by the Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Praluent</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> million, an increase of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.5%</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">driven by Europe and China</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thymoglobulin</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;117 million, an increase of 12.8%, driven by China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Aubagio</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales decreased by 74.7% to &#8364;102 million, reflecting the loss of exclusivity in the US in March 2023 and the competition from generics across all regions, including Europe where generics entered the market at the end of September 2023. The negative impact is anticipated to continue during 2024 as the losses of exclusivity annualize.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eloctate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;86 million, a decrease of 24.6%, reflecting patients converting to </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cerdelga</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;83 million, an increase of 15.1%, reflecting continued growth in the US, Europe and favorable shipment pattern.<br><br><br><br><br><br><br><br><br><br><br></font><font style="background-color:#ffff00;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  4                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_22"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-top:15pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Polio&#47;Pertussis&#47;Hib vaccines incl. Boosters</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Meningitis, Travel and endemic vaccines </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Influenza vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+38.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-100.0%</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased by 5.6% to &#8364;1,177 million driven by strong Beyfortus uptake partly offset by the absence of COVID-19 vaccines sales this quarter compared to &#8364;167 million in Q1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Polio&#47;Pertussis&#47;Hib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (PPH) vaccines sales, including Boosters, decreased by 0.5% to &#8364;636 million. Positive Rest of World sales driven by performance and favorable phasing were offset by declining sales in the US, where Vaxelis became market leader in the three-dose primary series market at the end of 2023. Vaxelis in-market sales are not consolidated by Sanofi but profits are shared equally between Sanofi and Merck &#38; Co.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Meningitis, Travel and endemic</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> vaccines sales increased by 7.7% to &#8364;286 million reflecting a favorable US Centers for Disease Control and Prevention buying pattern and increased MenQuadfi penetration in Europe.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales reached &#8364;182 million, reflecting late deliveries in the US and new implementation of &#8220;All Infant Protection&#8221; programs in Chile and Australia. No Beyfortus sales are expected in Q2 2024 due to the early delivery in Q1 and the specific seasonality.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Influenza vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales reached &#8364;73 million, benefiting from positive phasing with earlier deliveries to Southern Hemisphere countries compared to Q1 2023.<br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_25"></div><div style="text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Biopharma business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BOI of Biopharma decreased by 15.2% to &#8364;2,365 million. At CER, Biopharma BOI decreased by 5.7% reflecting lower gross profit ratio, higher R&#38;D expenses, and lower capital gains from divestments of medicines&#47;portfolio streamlining as compared to Q1 2023. The ratio of BOI to net sales decreased by 5.5pp to 26.5% (28.3% at CER).<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  5                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_28"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline update</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi has 77 projects in a pipeline across four main therapeutic areas (Immunology, Rare diseases, Neurology, and Oncology) and Vaccines, including 39 potential new medicines (NMEs) and vaccines. The following section highlights significant developments in the late- and mid-stage pipeline in the quarter and recently&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Highlights of the quarter</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:27.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory approvals</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; pediatric eosinophilic esophagitis (EoE) (US)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; chronic spontaneous urticaria (CSU) (JP)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beyfortus &#8211; RSV prevention (JP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory submission acceptance</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; COPD (US, EU, CN) (US priority review, PDUFA June 27)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 data readouts</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rilzabrutinib - immune thrombocytopenia (ITP) (primary endpoint met)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Major pipeline advancements</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SP0125 &#8211; toddler RSV vaccine (phase 3)</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dupilumab)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">The US Food and Drug Administration (FDA) updated the label for </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">atopic dermatitis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (AD), adding efficacy and safety data for patients aged 12 years and older with AD with uncontrolled moderate-to-severe hand and&#47;or foot involvement.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">The FDA approved </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">eosinophilic esophagitis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (EoE). Dupixent is now the first and only medicine approved in the US specifically indicated to treat these patients.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">The Ministry of Health, Labour and Welfare in Japan granted regulatory approval for </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">chronic spontaneous urticaria</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet medical needs. A regulatory submission is also under review in the European Union based on data from the LIBERTY-CUPID clinical study program.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">The FDA accepted for Priority Review the supplemental Biologics License Application for </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">chronic obstructive pulmonary disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (COPD). The target action date for the FDA decision is June 27, 2024. Regulatory submissions are also under review in the European Union and China.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">amlitelimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OX40L mAb)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results from part 2 of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">amlitelimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> STREAM-AD phase 2b study showed sustained improvement of signs and symptoms for 28 weeks in adults with moderate-to-severe </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AD</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> who previously responded to amlitelimab and continued treatment. High responder rates were also observed in participants who were taken off amlitelimab. The safety profile was consistent with part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified. These results were presented as part of a late-breaking session at the American Academy of Dermatology 2024 Conference in San Diego and support the dosing of once every 12 weeks now being assessed in a larger phase 3 clinical program (OCEANA). Enrollment of the four main AD studies is on track and designed to evaluate the on- and off-treatment efficacy and safety in adults and adolescents, with a regulatory submission anticipated in 2027.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">itepekimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (IL33 mAb)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first participants were treated in the phase 2 study evaluating </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">itepekimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">bronchiectasis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (clinical study identifier&#58; NCT06280391).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (BTK inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results from the RILECSU phase 2 study showed that </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly improved itch, hives and urticaria in adults with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">moderate-to-severe CSU</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> whose symptoms are not adequately controlled by H1-antihistamines. The data were presented in a late-breaking poster at the 2024 American </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  6                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Academy of Allergy, Asthma and Immunology Annual Meeting in Washington, DC, US and form the basis for the phase 3 program which is on track to start in H2 2024.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, results from the second (high-dose) cohort of the ACT17208 phase 2 study of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> showed a higher relative reduction magnitude in loss of asthma control and confirmed meaningful improvement in symptoms with overall good safety in patients with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">moderate-to-severe asthma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The data are anticipated to be presented at the upcoming American Thoracic Society International Conference.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">frexalimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD40L mAb)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">frexalimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sj&#246;gren&#8217;s Syndrome</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (SjS), an immunological disorder with currently no approved disease-modifying treatments, was discontinued based on the findings of a phase 2 study. The 84-patient study evaluated the therapeutic efficacy of one dose level of frexalimab versus placebo over 12 weeks in adult patients with primary SjS, assessed by the change of the EULAR SjS Disease Activity Index (ESSDAI). The data confirmed pharmacologic activity and well-tolerated safety profile but not the necessary efficacy outcomes to continue to move forward the development in this indication. Development of frexalimab continues in relapsing multiple sclerosis (RMS) and secondary-progressive multiple sclerosis (SPMS) in phase 3, and type 1 diabetes and systemic lupus erythematosus in phase 2.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rare diseases</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (avalglucosidase alfa)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New data from the Mini-COMET phase 2 long-term extension study of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in pediatric patients with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">infantile-onset Pompe disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (IOPD), suggested that it meaningfully improved ptosis, or drooping eyelid, over nearly three years. Data were featured at the 20th annual WORLDSymposium</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, along with positive safety debut data from the Baby-COMET phase 3 study, the first study in never-before-treated patients with IOPD, and the first study in over 20 years of any treatment in na&#239;ve IOPD patients. The phase 3 Baby-COMET study is currently ongoing and is expected to read out in 2025, followed by a regulatory submission later in the year.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">venglustat</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (GCS inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AMETHIST phase 3 study of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">venglustat</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GM2 gangliosidosis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was discontinued based on the absence of positive trends on clinical endpoints. The data reinforced the favorable safety profile and do not impact the other indications currently being tested.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (BTK inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> met the primary endpoint of durable platelet response in the LUNA 3 phase 3 study in adult patients with persistent or chronic </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">immune thrombocytopenia</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ITP), showing clinically and statistically significant result in a population of patients with primary ITP that had been refractory to prior therapy. The safety profile of rilzabrutinib was favorable and consistent with that reported in previous studies. Regulatory submission is planned for H2 2024. Previously, rilzabrutinib was granted Fast Track Designation and Orphan Drug Designation by the US FDA.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurology</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">oditrasertib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (RIPK1 inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The phase 2 study of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">oditrasertib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also known as SAR443820) in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">amyotrophic lateral sclerosis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ALS) was discontinued due to the primary endpoint of improvement based on ALS Functional Rating Scale-Revised (ALSFRS-R), the conventional assessment of physical function in activities of daily living for patients, not being met. The parties are committed to sharing the full efficacy and safety data at a forthcoming medical meeting.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi will continue the K2 phase 2 study of </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">oditrasertib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in participants with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">frexalimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD40L mAb)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 data for </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">frexalimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in MS were published in The New England Journal of Medicine, demonstrating that frexalimab significantly slowed disease activity in people with RMS, corresponding to an 89 percent and 79 percent reduction in new Gd+ T1 brain lesions at 12 weeks in the high- and low-dose treatment arms compared to placebo, meeting the study&#8217;s primary endpoint. Findings also showed both doses of frexalimab provided a significant reduction in new or enlarging T2 lesions, a secondary endpoint of the </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  7                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study. Phase 3 studies in RMS and non-relapsing secondary-progressive MS (nrSPMS) are initiated with regulatory submission expected in 2027.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nirsevimab)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a long-acting monoclonal antibody, was approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SP0125</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (live attenuated RSV vaccine for toddlers)</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study evaluating </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SP0125</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the prevention of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">respiratory syncytial virus (RSV) in toddlers</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered phase 3.<br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  8                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Anticipated major upcoming pipeline milestones</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#330e74;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#330e74;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Medicine&#47;vaccine</font></td><td colspan="3" style="background-color:#330e74;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#330e74;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="5" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H1 2024</font></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CSU</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (EU)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Kevzara</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Polyarticular juvenile idiopathic arthritis</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Multiple myeloma (MM), front line (1L) (IMROZ study)</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">MenQuadfi</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Meningitis six weeks+</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="16" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H2 2024</font></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (EU)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CSU</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Bullous pemphigoid (BP)</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rilzabrutinib</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">ITP</font></div></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">IgG4-related disease</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Warm autoimmune hemolytic anemia</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">amlitelimab</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Asthma</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Anti-TL1A</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Inflammatory bowel disease</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data (interim analysis)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">fitusiran</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Hemophilia A&#47;B</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">RMS</font></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="12" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">nrSPMS</font></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="12" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, relapsed&#47;refractory (R&#47;R) (IRAKLIA study), subcutaneous</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, newly diagnosed (GMMG study)</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">MenQuadfi</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Meningitis six weeks+</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2025</font></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (CN)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CSU</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">BP</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">itepekimab</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">amlitelimab</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Hidradenitis suppurativa (HS)</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Alopecia areata</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">eclitasertib</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Ulcerative colitis</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">frexalimab</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Systemic lupus erythematosus</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">IRAK4 degrader</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">AD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">HS</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Oral TNFR1si</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Psoriasis</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Rheumatoid arthritis</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">lunsekimig</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Asthma</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">TNFa&#47;OX40L</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">HS</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Nezviazyme</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">IOPD</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">venglustat</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Fabry disease</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Primary progressive MS</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, R&#47;R (IRAKLIA study), subcutaneous</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, newly diagnosed (GMMG study)</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">SP0256</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">RSV older adults</font></td><td colspan="3" style="border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">SP0087</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Rabies</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">An update of the Sanofi pipeline as of March 31, 2024, is available at&#58; https&#58;&#47;&#47;www.sanofi.com&#47;en&#47;our-science&#47;our-pipeline.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  9                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_31"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Consumer Healthcare </font></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Change </font></div><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">at CER</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seasonal symptoms &#38; pain relief </font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wellness brands </font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+26.3%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-5.8&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Healthcare (CHC) sales increased by 9.0% to &#8364;1,525 million supported by growth in the Rest of World region and the US which included the acquisition of Qunol. The divestments of non-core products had a negative impact of -1.6pp, mainly reflected in the Others category in the first quarter. Excluding divestments and the Qunol acquisition, CHC sales growth was 5% in the quarter.<br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_34"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CHC business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BOI of CHC decreased by 11.6% to &#8364;472 million. At CER, the BOI of CHC was up 3.0% mainly reflecting the consolidation of Qunol. The ratio of BOI to net sales decreased by 4.7pp to 31.0% (33.8% at CER) compared to Q1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the quarter, Sanofi reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in US state courts outside of Delaware. Assuming the agreement concludes in due course, Sanofi is settling these cases, not because Sanofi believes the claims have any merit, but rather to avoid expenses and ongoing distraction of the litigation, and with no concession of liability. This resolution is not anticipated to have any material financial impact.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  10                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_37"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Corporate Social Responsibility update at the end of the Q1 2024</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:102%">Access to healthcare</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sanofi Global Health Unit&#58; making a difference for our patients in low- and middle-income countries</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi&#8217;s Global Health Unit (GHU) works to address today&#8217;s many growing healthcare challenges &#8211; with a focus on countries with the highest unmet medical needs &#8211; through a self-sustained not-for-profit social business model.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi&#8217;s GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that end the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered essential by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi's GHU aims to reach two million people with non-communicable disease (NCD) care in its 40 countries in scope by 2030. Since its creation in 2021, the GHU has made significant progress towards its objective, having already treated 506,130 NCD patients in 31 countries as of the end of March 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support the set up and development of sustainable healthcare systems, the GHU is also working closely with local communities, authorities and non-governmental organizations to develop disease awareness programs and establish partnerships to drive better care through&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.65pt">strengthening supply chains&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.65pt">conducting medical training&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.65pt">providing services to patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi's GHU has engaged with Ministries of Health and other partners in several countries, including Rwanda, Uganda, Tanzania and Cambodia. As of March 2024, the GHU pilots 44 active partnerships in 21 countries. Selected examples of projects supported are described below&#58;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Name</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Therapeutic Area</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Country(s)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Activity pillar(s)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Overview and progress in numbers</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">PharmAccess</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Zanzibar</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Patient Care model</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The project is an integrated patient-centered model of care aiming at improving diagnosis and disease management for patients with cardio-metabolic diseases through a care bundle consisting of access to patient group meetings, digital self-management support, remote care and medications.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">CHAZ FBO Zambia</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Zambia</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Scaling Patient Care services with<br>faith-based organizations</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The primary goal is to institutionalize NCD Prevention WHO Best Buys as a standard of care within the church health institutions participating in the project. It includes building the capacity of health workers and community educators in church health institutions in diabetes and hypertension prevention and management, raising awareness of common NCD risk factors, and providing diabetes and hypertension diagnostic and treatment services in the selected church health institutions.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">WCEA</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Malawi, Tanzania, Sierre Leone, Zimbabwe, Uganda</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Online HCP Training</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Online NCD training of healthcare professionals across multiple countries.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">CNSS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Djibouti</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Empowering HCPs and supply chain actors</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The specific objectives of this partnership are focused on strengthening advocacy and knowledge about NCDs, increasing the capacity of healthcare professionals for better management of NCDs and of supply chain actors, while building a sustainable procurement mechanism for affordable access to treatment.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Touch Foundation</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cardio<br>Diabetes</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Tanzania</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Strengthen Supply Chain</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The primary goal is to improve supply chain management for NCD medicines and patient tracking at each facility to ensure patients are adhering to treatment.</font></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  11                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Action 4 Diabetes (A4D)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Diabetes (type 1)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cambodia, Laos, Myanmar</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Care for Type 1 Diabetes Patients</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Action 4 Diabetes focuses on type 1 diabetes patients and includes healthcare professional training, patient services, support in monitoring blood glucose levels and access to insulins, to increase efficiency in the management of type 1 diabetes patients. A4D also holds diabetes camps for patients and their families to build awareness and understanding.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">City Cancer Challenge</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Oncology</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Cambodia<br>Rwanda</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Health System Strengthening</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Working with City Cancer, the objectives are to create city-wide oncology stakeholder leadership groups and complete situational analysis and needs assessments of oncology services (including digital oncology services), forming the basis for a successful approach to empower and strengthen the health system.</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cancer and work&#58; Sanofi supporting health and wellbeing in the workplace</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi has launched &#8216;Cancer &#38; Work&#58; Acting Together&#8217;, a program which covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It will allow employees to incorporate further flexible work arrangements to better navigate cancer and work and will have access to a network of volunteer colleagues trained to help them navigate from initial diagnosis through the treatment journey and return to work. The program is also designed to better equip managers to support members of their team who are affected by cancer. Throughout 2024, Sanofi also intends to implement coverage of miscellaneous non-medical expenses. Moreover, Sanofi permanent employees will become eligible for an unpaid caregiver leave which allows them to carry out caregiving duties for their close family member suffering from a critical illness</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several volunteer employees in France, with complementary expert skills and experience as patients, caregivers or managers, started the initiative. The program has since grown to a network of 27 partner teams with one team at each Sanofi site in France, with 150 members who share feedback and best practice. More than 350 employees have benefited (42% sick employees, 30% caregivers, 28% managers).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program &#8220;Cancer &#38; Work&#8221; has started to roll out globally in early 2024 and is part of our programs supporting health and wellbeing in the workplace. This complements other initiatives already launched for employees such as the gender-neutral parental leave, allowing all new parents 14 weeks of paid leave to welcome a new child into their lives.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">1. Specific criteria identifying the conditions and circumstances that are eligible for coverage under this program might be governed by the terms and conditions of country-specific policies or legal requirements.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%"><br></font></div><div style="text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ESG ratings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Latest Sanofi ESG rankings&#58;</font></div><div style="text-align:justify"><img alt="capturedecran2024-04x15a14.jpg" src="capturedecran2024-04x15a14.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:716px"></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  12                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_40"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Q1 2024 financial results</font></div><div style="margin-top:3pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business net income</font><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi generated</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> net sales</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of &#8364;10,464 million, an increase of 2.4% (up 6.7% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other revenues</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased by 2.0% (up 9.8% at CER) to &#8364;654 million, including higher VaxServe sales of non-Sanofi products of &#8364;407 million (up 5.6% at CER).</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gross Profit</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decreased by 1.2% (up 4.2% at CER) to &#8364;7,694 million. The gross margin ratio decreased by 2.6pp to 73.5% (74.4% at CER) compared with Q1 2023. This decrease mainly reflected a deterioration of the Biopharma gross margin ratio (from 77.7% to 75.1%) due to the product mix evolution (e.g. sales decrease of Aubagio, COVID sales) and unfavorable currency evolution. CHC gross margin ratio decreased from 67.0% to 63.9% due to product and country mix, as well as unfavorable currency evolution.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(R&#38;D)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses increased by 10.0% to &#8364;1,719 million. At CER, R&#38;D expenses increased by 11.8%, reflecting increased expenses in Vaccines (mRNA) and Pharma (pipeline acceleration).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (SG&#38;A) decreased by 0.1% to &#8364;2,605 million. At CER, SG&#38;A expenses increased by 2.9%, reflecting increased commercial investments and launch costs in Biopharma and Vaccines as well as higher CHC commercial expenses. The ratio of SG&#38;A to sales decreased by 0.6pp to 24.9% compared to Q1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operating expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;4,324 million (up 3.7% and up 6.2% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other current operating income net of expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were -&#8364;562 million compared to -&#8364;304 million in Q1 2023. Other current operating income net of expenses included an expense of &#8364;825 million (compared to an expense of &#8364;674 million in Q1 2023) corresponding to the share of profit to Regeneron from the monoclonal antibodies alliance, the share of profit paid by Regeneron towards development costs and the reimbursement of commercialization-related expenses incurred by Regeneron. This line also included &#8364;199 million of capital gains from divestments of medicines&#47;portfolio streamlining, compared to &#8364;307million in Q1 2023. Sanofi expects the amount of capital gains from divestments of medicines&#47;portfolio streamlining to exceed &#8364;500 million in 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share of profit from associates </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was &#8364;44 million compared to &#8364;33 million in Q1 2023 and included the share of US profit related to Vaxelis.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BOI) decreased by 14.7% to &#8364;2,843 million. At CER, BOI decreased by 4.2%. The ratio of BOI to net sales decreased by 5.4pp to 27.2% (down 3.3pp at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net financial expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;43 million compared to &#8364;7 million in Q1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">effective tax rate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased to 21.0% from 19.0% in Q1 2023. Sanofi expects its effective tax rate to be around 21% in 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased by 17.8% to &#8364;2,219 million and decreased by 7.4% at CER. The ratio of business net income to net sales decreased by 5.2pp to 21.2% compared to Q1 2023 (down 3.5pp at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business earnings per share</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(EPS) was &#8364;1.78, down 17.6% on a reported basis (down 7.4% at CER). The average number of shares outstanding was 1,248.8 million compared to 1,249.3 million in Q1 2023.<br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_43"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of IFRS net income reported to business net income (see Appendix 4) </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The IFRS net income was &#8364;1,133 million. The main items excluded from the business net income were&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">An amortization charge of &#8364;562 million related to fair value remeasurement on intangible assets&#58; 547 million (primarily Bioverativ&#58; &#8364;160 million, Genzyme&#58; &#8364;94 million, Provention Bio&#58; &#8364;53 million, Boehringer Ingelheim CHC business&#58; &#8364;45 million, Ablynx&#58; &#8364;42 million, Kadmon&#58; &#8364;41 million, Beyfortus&#58; &#8364;28 million and Qunol&#58; &#8364;20 million) and to intangible assets from separate acquisitions - measured initially at acquisition cost (licenses&#47;products)&#58; &#8364;15 million. These items have no cash impact.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Restructuring costs and similar items of &#8364;740 million mainly related to redundancy plans announced during Q1 2024 and separation costs of the CHC business.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Other gains and losses, and litigation charge of &#8364;79 million related to change in provision for litigation.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ee Appendix 3 for Q1 2024 consolidated income statement&#59; see Appendix 7 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  13                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A financial charge of &#8364;59 million related to the remeasurement of expected future royalty of Beyfortus US sales.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A &#8364;424 million tax effect arising from the items listed above, main</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ly comprising &#8364;105 million of deferred taxes generated by amortization of intangible assets and &#8364;272 million associated with restructuring costs and similar items (see Appendix 4).</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A loss of &#8364;81 million corresponding to the equity stake in EUROAPI.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Capital allocation</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Q1 2024 free cash flow before restructuring, acquisitions and disposals amounted to -&#8364;78 million, after negative change of net working capital (-&#8364;1,764 million), notably including the decrease of US rebates provisions (&#8364;980 million) following decision to cut Lantus list price effective January 1, 2024 and capital expenditures (-&#8364;512 million). After acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (-&#8364;253 million), proceeds from disposals</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8364;478 million) and payments related to restructuring and similar items (-&#8364;456 million), Q1 2024 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was -&#8364;309 million. The net debt increased from &#8364;7,793 million on December 31, 2023 to &#8364;8,534 million on March 31, 2024 (amount net of &#8364;9,181 million cash and cash equivalents).</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> N</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">on-IFRS financial measure (definition in Appendix 7).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  14                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_46"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221;, &#8220;potential&#8221;, &#8220;outlook&#8221;, &#8220;guidance&#8221; and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete capital markets or other transactions and&#47;or obtain regulatory clearances, risks associated with developing standalone businesses, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">All trademarks mentioned in this document are protected.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_49"></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Appendices</font></div><div><font><br></font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:12.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix&#160;1&#58;</a>&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024<a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> sales by </a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">medicine&#47;vaccine</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">&#47;business</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> and</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_52" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> geographic region </a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 2&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1<a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> 202</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">4</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> business net income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 3&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 <a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">202</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">4</a><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> consolidated income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_67" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 4&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_67" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Reconciliation of IFRS net income reported to business net income</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_70" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Appendix 5&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_70" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Change in net debt</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 6&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency sensitivity</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_82" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix </a>7&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i09e8658d8ace4fab8e0e4aec0a4cf8c0_82" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Definitions of non-IFRS financial indicators</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSR Dashboards</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Media Relations</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sandrine Guendoul </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 25 09 14 25 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">sandrine.guendoul&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Nicolas Obrist </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 77 21 27 55 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">nicolas.obrist&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Victor Rouault </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 70 93 71 40 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">victor.rouault&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sally Bain </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 617 834 6026 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">sally.bain&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Evan Berland</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> &#124; +1 215 432 0234 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">evan.berland&#64;sanofi.com</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investor Relations</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Thomas Kudsk Larsen</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> &#124; +44 7545 513 693 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">thomas.larsen&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Aliz&#233; Kaisserian</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> &#124; +33 6 47 04 12 11 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">alize.kaisserian&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Arnaud Del&#233;pine </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 73 69 36 93 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">arnaud.delepine&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Corentine Driancourt </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 40 56 92 21 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">corentine.driancourt&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Felix Lauscher </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 908 612 7239 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">felix.lauscher&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Nathalie Pham </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 7 85 93 30 17 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">nathalie.pham&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Tarik Elgoutni </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 617 710 3587 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">tarik.elgoutni&#64;sanofi.com</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  15                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_52"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 1&#58; Q1 2024 net sales by medicine&#47;vaccine&#47;business and geographic region</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2024 (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sales</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% reported</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of World</font></div></td><td colspan="3" style="background-color:#23004c;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Dupixent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,835</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+24.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+22.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,030</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+16.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">371</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+33.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">434</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+67.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">152</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+96.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+87.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">85</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+53.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+147.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+287.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">106</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+28.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+21.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">49</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+32.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+10.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+45.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Altuviio</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">122</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12300.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12100.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">115</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11600.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Rezurock</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">93</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+40.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+38.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+28.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+400.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cablivi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">59</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-14.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+66.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+94.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+80.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Enjaymo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+87.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+81.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+66.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Tzield</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total Pharma launches </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">606</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+90.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+84.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">408</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+99.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+45.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+141.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">321</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">56</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">119</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+9.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">146</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+44.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">360</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-19.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">112</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">92</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-5.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">156</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-21.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">262</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-18.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">155</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-11.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">104</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-16.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">238</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+6.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+0.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">213</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">253</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+2.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">126</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">63</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">191</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-16.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">60</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-21.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">130</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+27.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">214</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+9.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">48</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+42.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">102</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-74.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-75.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">41</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-85.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">52</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-56.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">121</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+16.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">38</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+42.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">117</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">34</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+30.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">105</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+2.2&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+19.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+27.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-24.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-27.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">62</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-25.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-21.2&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">78</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">70</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">68</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">47</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+13.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+10.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+9.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+20.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-37.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+37.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+26.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-40.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-61.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-62.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-92.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-5.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,140</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-10.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">335</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">719</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Industrial Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">157</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+16.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">156</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-114.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total other medicines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,321</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-7.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-12.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,055</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-24.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,374</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-5.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,892</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+1.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,762</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+6.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+2.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,493</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+4.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,865</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+2.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,404</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+11.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Influenza vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+38.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-80.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">67</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+55.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib vaccines &#38; Boosters</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">636</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">164</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">363</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">182</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">114</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">61</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">286</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+5.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">137</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">48</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+38.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,177</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+5.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+0.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">420</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+30.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">165</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-48.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">592</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+22.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,939</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+6.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+2.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,913</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+7.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,030</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-4.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,996</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+13.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Healthcare</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,525</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+9.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+2.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+10.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">450</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">672</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+14.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,464</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+6.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+2.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,316</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+7.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,480</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">-4.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,668</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+13.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  16                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_58"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Appendix 2&#58; Business net income statement</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.860%"><tr><td style="width:1.0%"></td><td style="width:17.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2024</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consumer Healthcare</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Group</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2024</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">8,939</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">8,727</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">2.4%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,525</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,495</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">2.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10,464</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10,222</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">2.4%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">639</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">626</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">2.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">654</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">641</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">2.0%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,862)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,569)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">11.4%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(565)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(508)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">11.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-250.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,424)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,079)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">11.2%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.0%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(29.4%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(37.0%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(34.0%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(30.1%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Profit</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,716</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,784</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-1.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">975</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,002</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-2.7%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-250.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,694</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,784</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-1.2%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">77.7%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">63.9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">67.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">73.5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">76.1%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,675)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,510)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">10.9%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(44)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(53)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-17.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,719)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,563)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">10.0%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(18.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(17.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(2.9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(3.5%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(16.4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(15.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,093)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,124)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(514)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(484)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">6.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">100.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,605)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,607)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.1%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(23.4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(33.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.4%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(25.5%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current operating income&#47;expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(617)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(386)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">54</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(562)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(304)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;loss of associates* and joint ventures</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non controlling interests</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(9)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,365</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,789</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-15.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">472</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">534</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-11.6%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-40.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,843</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3,333</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-14.7%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.5%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">32.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">31.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">35.7%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">27.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">32.6%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(43)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expenses</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(581)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(627)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Tax rate**</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">21.0%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">19.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="9" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,219</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,699</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-17.8%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">21.2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.4%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business earnings &#47; share(in euros)***</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1.78</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2.16</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-17.6%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Net of tax.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Determined on the basis of Business income before tax, associates, and non-controlling interests.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*** Based on an average number of shares outstanding of 1,248.8 million in the first quarter of 2024 and 1,249.3 million in the first quarter of 2023.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  17                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_64"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 3&#58; Consolidated income statements</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.636%"><tr><td style="width:1.0%"></td><td style="width:70.123%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,464</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,222</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,439)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,079)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,679</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,784</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,719)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,563)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,605)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,607)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,006)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(740)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(740)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(240)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other gains and losses, and litigation</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,449</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,463</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income before tax and associates and joint ventures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,347</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,456</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(459)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) of associates and joint ventures</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,146</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,009</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,133</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,995</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IFRS Earnings per share (in euros)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.91</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  18                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_67"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 4&#58; Reconciliation of Net income attributable to equity holders of Sanofi to Business net income</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.798%"><tr><td style="width:1.0%"></td><td style="width:68.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Q1 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,133</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,995</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other gains and losses, and litigation </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial (income) &#47; expense related to liabilities carried at amortized cost other than net indebtedness</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax effect of the items listed above&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(424)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(101)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(94)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(272)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(49)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(25)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other tax effects</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,219</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IFRS earnings per share </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in euros)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.91</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;padding-left:7.21pt">Of which related to amortization expense generated by the intangible assets measured at their acquisition-date fair values&#58; &#8364;547 million in the first quarter of 2024 and &#8364;468 million in the first quarter of 2023.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;padding-left:5.66pt">Based on an average number of shares outstanding of 1,248.8 million in the first quarter of 2024 and 1,249.3 million in the first quarter of 2023.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:3pt;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  19                   </font></div></div></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_70"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 5&#58; Change in net debt</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.766%"><tr><td style="width:1.0%"></td><td style="width:70.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Q1 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,219</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation &#38; amortization &#38; impairment of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(370)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,198</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,746</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Working Capital</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,764)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(627)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(512)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow before restructuring, acquisitions and disposals</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(78)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,672</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangibles assets, investments and other long-term financial assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items paid</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(456)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(309)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,537</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of investments in consolidated undertakings including</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">assumed debt </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of treasury shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(302)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in net debt</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(741)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,132</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of period</font></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,793</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,437</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Closing of net debt</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,534</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,305</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Free cash flow includes investments and divestments not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Includes transactions that are above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  20                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_79"></div><div style="margin-bottom:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 6&#58; Currency sensitivity</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 business EPS currency sensitivity</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variation</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business EPS Sensitivity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US Dollar</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.05 USD&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+5 JPY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.2 CNY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.4 BRL&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.01</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Ruble</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10 RUB&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.01</font></div></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:87%">Currency exposure on Q1 2024 sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:87%"> </font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US $</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euro &#8364;</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexican pesos</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian ruble</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">British Pound</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australian $</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canadian $</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:80%">Currency average rates </font></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.073&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.085&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yen</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.049&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.152&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">+13.4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yuan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.821&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+6.4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Real</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.575&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">-3.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Ruble</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.351&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.637&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+25.9%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  21                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:6pt"><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_82"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 7&#58; Definitions of non-IFRS financial indicators</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company sales at constant exchange rates (CER)</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we refer to changes in our net sales &#8220;at constant exchange rates&#8221; (CER), this means that we exclude the effect of changes in exchange rates.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for </font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the previous period.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation of net sales to Company sales at constant exchange rates for Q1 2024.</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,464</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(444)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company sales at constant exchange rates</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,908</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business net income</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi publishes a key non-IFRS indicator. Business net income is defined as net income attributable to equity holders of Sanofi excluding&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">amortization of intangible assets,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">impairment of intangible assets, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">fair value remeasurement of contingent consideration related to business combinations or to disposals,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">expenses arising from the impact of acquisitions on inventories</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">restructuring costs and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">other gains and losses (including gains and losses on disposals of non-current assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">),</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">costs or provisions associated with litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">upfront payments and regulatory milestone payments recognized in the line item Other operating income and arising from transactions outside the scope of Sanofi's ordinary activities,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">financial (income)&#47;expense related to liabilities carried at amortized cost other than net indebtedness, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">tax effects related to the items listed above as well as effects of major tax disputes,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the items listed above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1) Reported in the line items </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Gains and losses on disposals, and litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, which are defined in Notes B.16. and B.17. to our consolidated financial statements.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Free cash flow </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow is a non-IFRS financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from Sanofi&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), for debt repayment, and for capital return to shareholders. Free cash flow is determined from the Business net income adjusted for depreciation, amortization and impairment, share of profit&#47;loss in associates and joint ventures net of dividends received, gains &#38; losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount of the transaction above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i09e8658d8ace4fab8e0e4aec0a4cf8c0_88"></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  22                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Appendix 8&#58; CSR dashboards</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data are presented in YTD unless stated otherwise.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:18.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Topic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambition</font></td><td colspan="6" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progress</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Affordable access </font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Global Health</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reach 1.5 million NCD patients by 2026 (cumulative since 2022) and 2 million by 2030<br></font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,889 patients treated in 18 countries</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 active healthcare partnerships in 21 countries</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 investments signed through the Impact Fund (cumulative since launch)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,396 patients treated in 19 countries</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 active healthcare partnerships in 14 countries</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 investment signed through the Impact Fund</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vials donations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donate 100,000 vials a year to treat people with rare diseases</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112 patients treated</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,287 vials donated</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065 patients treated<br>21,542 vials donated</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Access Plans </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Develop a Global Access Plan for all new products to make them available within two years after first launch</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 Global Access Plans initiated or developed covering more than 14 indications</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 Global Access Plans initiated or developed covering more than 12 indications</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&#38;D for unmet needs</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FY 2023</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FY2022</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sleeping sickness</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Develop and supply innovative treatments to support the elimination of sleeping sickness by 2030</font></div><div><font><br></font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data updated annually, next update in Q2 2024</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 million patients tested<br>837 patients treated</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polio</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provide inactivated polio vaccines (IPV) to UNICEF for GAVI countries to support polio eradication efforts</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 million IPV doses supplied to UNICEF for GAVI countries</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 million IPV doses supplied to UNICEF for GAVI countries</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pediatric cancer treatment development</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Develop innovative treatments to eliminate cancer death in children</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 assets undergoing pre-clinical assessment</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 asset in clinical study</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 assets undergoing pre-clinical assessment<br></font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First pediatric patient dosed with 1 clinical asset in a clinical study (less than 2 years after the 1st adult patient was dosed with this compound)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Planet Care</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Climate change - Carbon footprint </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(CO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">emissions)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55% reduction in scope 1&#38;2 greenhouse gas emissions (CO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> equivalent) by 2030 (cumulative vs 2019 baseline) to contribute to carbon neutrality by 2030 and net zero emissions by 2045 (all scopes)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% GHG reduction vs 2019</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38% GHG reduction vs 2019</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewable electricity</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% of renewable electricity in all our sites by 2030<br></font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eco-car fleet</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% eco-car fleet in 2030</font></div><div><font><br></font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44% eco-car fleet </font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43% eco-car fleet</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blister free syringe vaccines</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% blister free syringe vaccines by 2027</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next update at Q4 2024</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39% blister free syringe vaccines</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  23                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:18.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eco-design</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All new products to be eco-designed by 2025<br></font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 LCAs completed &#38; 5 in progress (new and </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">marketed products)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 LCAs completed &#38; 2 in progress (new and <br>marketed products)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In and beyond the workplace<br></font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2023</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Gender balance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambition of 50% of women in senior leadership roles by 2025</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ambition of 40% of women in executive roles by 2025</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engagement with communities</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engage socially and economically with all communities where we operate<br></font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next update in Q2 2024</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,240 volunteers<br>75,376 hours</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From Leaders to Citizens</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% of Sanofi leaders have CSR in their development path</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70% of the leaders have completed the eLearning phase<br><br>30% of the leaders have completed the full program</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71% of the leaders have completed the eLearning phase<br><br>30% of the leaders have completed the full program</font></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">End.</font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  24                   </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>capturedecran2024-04x15a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capturedecran2024-04x15a14.jpg
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MF3<(*>#G?9QA *RFWY/!O"\)N;^G/R+/KFG>1QL$0'H? .V!;)$P:]:'GO[
M "+R*R 'E($&T $&,Y79 D?@"CR!+PA *HX"RP ;)")5"\$*D ,V@#Q0 ':
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ME7PC19#2DV)(+9/*EBJ1.B%U2^JU-$%:7]I=FB6]5KI<^I3T?>EQ&8J,A4R
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MCG7^Q7G 1<N%Y5+M\LQ5QY7C6N/Z@F'(2&(<8;QQ,W<3NC6Y3;@[N*]Q;_=
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MG=]_J/N?%HBS_LW^"UWR K;T5)0N    5F58269-30 J    "  !AVD !
M  $    :       #DH8 !P   !(   !$H ( !     $   /IH , !     $
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M( (B( (B( (B( (BT#T$)*0?)N[-S<TH*2E!8V/C82I1Q8B "(B "(B "(B
M"(B "(B "/0V KZ>4.&:FAI\\,$'V+QY,[9OWX[4U%0,'CP865E9F#Y].F)B
M8GI"-?>K#N^__SZ^__WO8\6*%:BKJT-86!A^]*,?X99;;L&;;[[I\CS[[+,Q
M<.# +N?_X8<?PN_W[W7_I*0D''OLL1WV.QB\R\K*L&;-&JQ=NQ:;-FUR;39T
MZ%",'CT:4Z=.[5!F3U_Q[KOO(C\_'P,&#,"YYY[;TZNK^HF "(B "(B "(B
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M__#BQ8N1DY/C3.5->,S(R,"X<>-@/MZ=::?7K5L',]<>-&B0V\]\JLV_VS3
M9DIOFFXS$=]=*B\OQYPY<V#"MRT???31./'$$YT?=N@QIE6V?3P3?OO]WGOO
MN5W,3WS:M&G.7-W*MF1Y>,*[6W$(_AP(;_-_]P3TM+0T9T*?F9G9:2W'CQ^/
MQQY[#%_[VM<<UTYWZF1E?7T]YLZ=Z[:<?/+)3NMMYOG6-J6EI3 3>FLWJXOY
M]]O'N!87%[M]K?UL(,3V"4W&V*P6+(6V@_VV:\YB'EA:OWZ]T_S;>=DY>.E
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M0R!42/<=.:>M,Q6!PT? ?-UGS)B!(4.&.(L+L_0P-XZY<^<B)R?'5<2"WTE
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M( (B( (B( (B( (B( (B( *]C("$]%[68*JN"(B "(B "(B "(B "(B "(A
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M@ B(@ @<,00DI!\Q3:T3%0$1$ $1$ $1$ $1$ $1$ $1Z.D$)*3W]!92_41
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M-5&3'L;O[)ID!*KKD5=9@3 *\BF^,+>MJKD8B[8NXA!U$\Z;?BYB^4])!$1
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M$3XD'OV2^R,RH0%1 S,1O:( =85%F'[M>0AD1:*1H\35]?5\)?&=T_+>,05
M,P?[+6\ZUZ&RJI*_?8B*RN#R#C2D5**PM@[S-BW @(S1'!1(XU[NQ=4#B!S>
M*JQ?DX]-ZW:VZD9\41&8-'D0!@U)A061W;BF #E;BFVF5)<:Z3YPWF>.1G2,
M#]NR2[!L<2Y=^\V5SO@#1T\=@JRA:=B\K@ ;UQ?2@-(.#$-LG \S3AZ-^,0H
M5%?68^W*?!3DE;.IK*V  0,3,>WX8>SVA6/+^IU8O2+/+5M'(C$Y%A..'H3^
M ^@FV9)6+=V&[$U%KA]CAIO."H+E#\I*Q<BQ [!EPTX4;"^G8L+" P:0GIZ
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M^,%O/H-W7UN!YQY?@+2,1'+WN?8:/J8_CIDV!!5%5;CEFJ<P>'@_Q'&*/>L
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M3&L^9OQ 5WYC0Q.W;75YV+'1')P93!/ZY%0J!4*2Y15NHP)L4QLV=8(^KY6
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M*_FX#\(Q;?>XHP:Z8'*WWW,)MG-J-4_8MFMXY-AT#!R<C!]RJK6"W+*6XTB
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ML39_N82%( 9F[>^]_94</V6B)&?&RP4#^\L["$A27PT!#?P 8WS+Y&?]U\J
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MDUO_\9C,_?-=!UXS' 2, ,P?LZ$\7;-E&TSLM\@NN&=%@_=A3]0U-,I7*]9
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M]X&IR;B'MXTK,?<QWL0$6&W&0$!P-%(O'-#1>*NN?T\>\,$)#?'&8.$EH0B
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MNYNA '$(#!O:?,2MH57B0I-D\ICC9-JP,9*6F JF'HP-ZC=!YW[4.^Q[%V,
M,%_,%7;@&X!@?;3P<5"[_#HN$;[]CK7"4$S)%T++VFEGB;%O"#3?D1@+N28(
MI/DZS./K.23B,\K77R8&A\)"@BG$;')*6+B\N8<99T3.CD^0ZRLKY(2U*^6F
MV'AY"-KXE[*R92RRYUC$OMNRL51>>GP!!)M<4SO&6G=$D9\P+5.FGF3%W>#^
MOKM>\ ;FC-[.?.74./=$%)B_]<4".0OIHJWH[SV5^[;[_!![BY_>R)L"^&#'
M_&Z5X7H@+#C0^MGC-R/*.T>59SHZDA$ '"-Z.&72>WPT=.?W0@"#8CO,S<FH
MMV]_%UHB:@$[!C\<:RU;AK1L2>(1@H&DN1B<5C48;C#K-&\WIIF.0=2,PGB1
MQ1V#-P-.F<!1J+MF%\K7H$KG 14FS>XPC8V$+RLTJ4H_#@(],>?.5V:T:3=;
M/193R)$>?@Y<-\;*BOQ;I7#/.L3Q8? Y3.3L1L.D=/0[=YA-<Z"C.NS I,]<
MJ/239R16/P0&S$G\I<0$G8YC*&9KQ&DZI#GCSVWV$9EA*UL!&5YJ>9N<M-]D
M?%F&C+;%,),))Z/.WV2\>1ZUZ-26T\R>##/+\YN,O\50\S>% 996G6V@]ISM
M(,//XS3KYS?KM<KS.*_'W/$\UV[W,>59EU7N8,\;K]77R!.X*RD"BL"A(<!9
MP1W,,T*08-R']0ZMYZ#!BPR)D58P9R&^L9)87R8U;I\CQWF+?+ERF915-\)?
M&E)=C#$VN&_5@<NO8@P3N.2%!(;)J.1!,C0U23+C,R0U-AL665A#8-Q!];@8
MV\4)B3^4#H: @_EV.)E998%\)W&J9P"_3N*XSQ\&7D:YV7>06XMKJN6VK7D2
MAKF#X__"*K@XHF.P:>BNS/[R*JR&_KI]F_PF-57.B=Y?S+B[M%J^_F@CA-,.
M<W>>ZNGM(4DISB;2?;M_XZ/"Y;)39\A?GG\5\-AD(G*;,YJ['7,LK41V(I@<
M_<0W[RJ0/US]4P=X^M?E$= 5K<MW4=]LH WIUFR1$Z2]KDA:2V'VWAFL"O>#
M2;6M9H<TUY>*&QAU-\\H[(+DDZF]J![UCG+,B:W4U&'@-&)S:/8:P<PW./PM
M.T=H"Q[ZG9%!]T^T]NCWMT: 4^)WG:AZ.Q=]"I-"3KSMB!;OY18K8U.?E3UU
MJV5S\?-2WK 8C%\]7,5:4 )EL=AB?YO:J&GGEEDID9EWQX+,6_P\$R4Y^ARD
M63L.VG-(Y/',<+W6#I-&2N([SO[6=W\TGT"FF.;I)#*]_'#!PP^W263&R81S
MG[7-;_XF\VQIU^D33R::94G<YG%G(O-NU6.5X74LIIX,O]4.?O-\?G@]DM4F
M,O!6W;P.ZU12!!2!8QL!C@(TJJ(!EB%\V^"G#@<K"0G+$/^V%+EB5IK)'7WR
M^%,A%*Z0W8C67E=;@V4&YB%OY/D.")1H" 3#X(L>ZA\B03"M]O:D@!^* ##O
M9BPR]3O&1URAXV+Z=5 $+,@.6K#W F;9Q\,0Y/OCXX/YGS0Y*$1N3D@V0>GX
M.Q_I>8LPWR <O13"!+JDJ1&!ZKJZA;+G:*'*I825@HU3R6%H)IO@$N2#>[[J
M]%/DA+$CY"WXB/_QO\]+$=*3-<)](-C/7]+B8V0&LEN=,WWR8=6BN\3-'\6-
M4";]*.[<(WYK/O A2C@%&G+XJI2OP<*[T\ )3<-$"":<P>3:/.!CZXL\Y,RC
M#B;+O96C)Y)\(2(E3L(W?%8;X5])+;M9I'/(M0C#+-*%V<+@YQXZT-JIWP=%
M@&PS\#2S%-E:ADXAX\8A@3N)L3/.^U=(7R]'G^(<:,N%)H,(X.9,] 5DG[)*
MFR" &<P-;1X(UA.8)</]_R!U33MD=]5\J:Q=+[6-)=+8N@=E\+RP+:C('>WQ
ML@6)MT<8(K8G0A,_'E%\AV"2@=\YCK?#A-'FAM)L-^NVFN[<"-TVS"V9W(,1
M-=86]53>8J)9IJ?CUKF]?9/1_[;T7:[S;:^AY14!1: /(4!-*IIK1C1N8%W
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M/1-^\H'B[^,A%:T4)CCBO1@O+39:YY6CX\'4NU $C@ "RJ0? =#UDHK D4.
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M14 14 04 45 $5 $% %%0!%0!%P+ 6727:L_M#6*@"*@""@"BH BH @H HJ
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M<+VL"N%@'Z>9H@3Y>F)&&"FQP/<+C[YV<8U[\MA00(^7__+=3$Y 7V&G!O6
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M;4V+;[7%)^*"E6V0"679=+=1*O_O[K6:)WG'6UB/VKSG3;NYUK9/6KVMW4]
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M"CLDI\0DGSN?.&UQ4;[%/7[<?AL"AH A8 @8 H9 ^R-@0GK[8VQ7, 0, 4/
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M\F]#>P)#P! P! P!0\ 0, 0, 4/ $# $#($*0<"$] II2'L,0\ 0, 0, 4/
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M_A\!FWX!UAP#?]RJTXCE!TP6GA!$6-^)UX/?[_?Y,O;=<@30;./1P$1-NZ"
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M:1.(]=-198KQ<B$N+>'="+P[>O1H-:)@L&*)#D$5^4#1/H37<!1WC#!XL!*
M&3Z )8Z<SQ)'VI.83P1=I#^B[()W@+]#8">(G%'I"&2$P?;9KDH_RTI6+ ((
MKWPZFGXS\5;WP?QI!2^[:N]EW$4C#BQ8IM2#3-:D!L,UCHFC7*@]VZ<]V@ K
M!-X**%#0VC)(E_I^T3XP7MY;A38BP F3!\'HNB*U9_MT]/,B8)!*!8:I$@B%
M$(2G0%M2P_AWM+JV$M+3[@W/(1@B_QQIY<IU/\_5UFU3KEATQ?ONJ/;YW:3;
M<VG7"N&P5I]E)6]Z80^ZI/,9U_#0(AL,UO2D>0FV>,:,&6I!9^XJ!^JH]FD)
M%@AU\ &MF;>9^[&R8XA!"/14#KQ<>[=-:W@WO$Y(79P6(#$-=X]__)OVH*TQ
MSD2)/H<2IISX[>C]=^3V^/'CE>\%JYJ.O+!=RQ!(0Z"MA.^T^N/[<5\CTKA1
M(P+MT08,_'[PQS).$)Y2*6G=.FZ^K9GH2[VVE7/JO5 I GI[MF=["^?^W@F@
MZ--&^GWV;0A4&@(M$;R;@P%6P^C<GS0OX1%F\TQS4"U<EI@8K8V+@?!W[;77
MY@GH7-5X.=<JXU5<F(ZW9!KN\7+^-^V1M#S$^I-'J'G?)J0W#R\K;0@8 BU$
M -<J(T/ $&@9 GZ=9LO.MK,, 4,@"0&;EY)0Z7K[L)Z;ITW'MXOAWO&81Z]8
M/GZ^T;NV;4/ $# $# %#P! P! P!0\ 0, 0, 4.@ A$P(;T"&]4>R1 P! P!
M0\ 0, 0, 4/ $# $# %#H#P1,"&]/-O-[MH0, 0, 4/ $# $# %#P! P! P!
M0Z "$3 AO0(;U1[)$# $# %#P! P! P!0\ 0, 0, 4.@/!$P(;T\V\WNVA P
M! P!0\ 0, 0, 4/ $# $# %#H (1,"&] AO5'LD0, 0, 4/ $# $# %#P! P
M! P!0Z \$3 AO3S;S>[:$# $# %#P! P! P!0\ 0, 0, 4.@ A$P(;T"&]4>
MR1 P! P!0\ 0, 0, 4/ $# $# %#H#P1,"&]/-O-[MH0, 0, 4/ $# $# %#
MP! P! P!0Z "$3 AO0(;U1[)$# $# %#P! P! P!0\ 0, 0, 4.@/!$P(;T\
MV\WNVA P! P!0\ 0, 0, 4/ $# $# %#H (1,"&] AO5'LD0, 0, 4/ $# $
M# %#P! P! P!0Z \$3 AO3S;S>[:$# $# %#P! P! P!0\ 0, 0J&(&WWWZ[
M@I_.'JT0 EU*2,]FL^Z&&VYP/_K1C]RNN^[J_O"'/[@Y<^84NO]V.?;WO_^]
M:+TKKKABDS(77WRQN_+**YOL+W7'R2>?[*PSEHJ6E3,$# %#P! P!)RKJZMS
MX\>/-R@, 4/ $"A+!"Z\\$+WP0<?Y.[]O__]K[OYYIO=QQ]_[(X[[CAW__WW
MYXX5VMAMM]W<N''C"A7I<L=XUADS9NA]O?'&&RK[-><F]]QS3_?FFV\VYY2R
M*=NEA/2[[[[;_>,?_W"GG'**._744]WTZ=/=IY]^VN%@(BP7HZ^__KI)D>^^
M^\XM6+"@R?Y2=Z"<&#9L6*G%.[S<[;??[A@ 4*#<>..->=>?,F6*^_.?_YRW
M+_[C]==?=W3 <J!77WW5_>I7OVIRJ__ZU[_<7__Z5]W_O__]S_WXQS_.^TR<
M.+').1VUX^BCC]9[.>*((]Q##SW449=UT7:%6=YCCSWTVFTQ<-(75UEE%7?9
M99?E/<];;[WECCKJ*+?++KNXQQ]_/'>,B6SOO?=V!QUTD)LP84)N?V=O3)TZ
M5=OF)S_YB3OAA!,<?:FAH4%OJ[F34FN5@9V-16NO?^NMM[HUUEC#'7C@@:VM
MRLXO(P3H+XQQGIAO86+ON><>9=!^\YO?N.>??]X?;O(]<^9,M]%&&S797VB'
M5YR__/++;O_]]R]4M.@QF,C1HT>[E5=>V05!D"L?'3_9F60 R!7N@AM@$QV?
M?_WK7^<8YO???]^=>^ZY.N]C=(&B#/F++[[8J?TX[?K,\XS1:50N@A!]),ZC
M\!MC6&LI+E1^\\TW*DQ^__O?=Y=>>FEKJ^\VYR-+K+WVVHZQYLLOO]3G?N&%
M%Y2'&SY\N,-XV;]_?S=BQ(B2,/GVVV]=?7U]266[2J&KK[[:(4- RR^_O(-W
M; [-G3LWQT\UY[QR*-NEA/2GGGK*;;WUUF[4J%$ZF3&0K+[ZZHHC SW[^?V?
M__Q'!?A##SW4K;;::NYG/_N9^^*++[0<+SO"%>4^_/!#=^>==SH&#2;GJZZZ
MJDF;W'???6[====UZZRSCMMQQQW=====Y^@TFVVVF3O]]-/='7?<X4:.'*F=
MB'MCHH<8_+;??GNWS#++N!-//+%)O<V]+A5P?R@EL,;_\(<_U&?C>9A((";Y
M??;91QG4K;;:2O<5NXX6:J-_/#L*%'#AX[5^" WKK[^^0V@M1(\^^FB>0%6H
M;&<>0Z#:;[_]W+WWWIMW&]S_L<<>ZUYZZ27=SSN&AI,/S"/'H\Q7WLD=\(-W
M]<@CCW0[[[RS._C@@W/WV=Z7CK9K=76U8L0U6SMP?O755ZH]QD*&8.L)9AU%
MP.Z[[^Y..^TT%<AY-S_ZZ",'H\X^^B^">E>AV;-GJS+C^../=UMLL86CS_AQ
MH[F34FN5@5T%DY;>!\SA8X\]YA#6C;H' O &,*E1X>)O?_N;>MK5U-2XQ1=?
MW T8,*"@DINQ&4&B.>05YS"],+^MH7_^\Y_NE[_\I8Y3F4PF5U5T_&1GD@$@
M5[@+;@P9,D3',VYMUJQ9*J#YN?/!!Q]4S*-C7)0A;PM<6P-)VO4WW713M_'&
M&Z=672Z"4(\>/70^AF]!:8V2B&UXV992DE!)7?"$]#'Z)<HSS[>V]#K=Y3P$
M<.:S:)MLL,$&.I8QUT%++;64\OU13# D;;[YYF[##3=4Q1[CBZ??_>YW.EYN
ML\TV#CX*@B=::ZVUW*JKKNJNO?9:W8>L\=.?_M1MN>66#MX$(P)&.)0#E(??
M7VFEE=PFFVRB%GU.@F^!]Z4>#$*T.?P7YR.OK+?>>BH;(*\P?O(L\,<H&RZZ
MZ")WVVVWZ;7'C!GCCCGF&,<W/#7WP;41UI'#H"29)^DYM'"E_A. NPR-'3LV
MD$8.I/$#T?8%#S_\L-Z;:)4">8$#&1CU\\X[[P1__.,?@[///EN/BX8V./_\
M\W6[5Z]>P0,//!#(0*)E1?@.9.((1&#0>OF.TK;;;AO(2Z.[WGOO/?U><LDE
M<T5D4@_FS9L7B.4N$,$Y$%=X/=:W;]] 7J: XR*@!MR36)(#>0D#8:*#EEQ7
ME F!=+S@K+/."N2E#D08"?[O__XO..RPP_2:.^RP0R"3GFZ_\LHK)5TG]R E
M;H!K*006,BAH45F2$(@%,Q"E1>Y4$:P"F>@"48 $TFD#F2 "F:CUP_[)DR?G
MRK+!OC777#,0A4APS377Z+&__.4OP4X[[:3[Q+J@[4T9W@__;LA$$/S@!S\(
M9/#1=X(3P48$H4 4,P'G28?7^C[YY!/=O\(**VC[\-[$B?=#)K) E!]ZKC_^
M[KOOZK/(H)9K#W^,;ZXA@GUT5[ML%VH?&<@#V@*2 2_@7D5Y%<A &,A 'HA0
MJ^\L^-!^8G%6C"A_SCGG:!E1>@7__O>_ ['NZG'>;;%8Z[N8A.O"A0N;M*L,
MRE09^/>9;?J&#/2!3 ;!$T\\P:X\2FK'0PXY)!#F6]\-40CERC_SS#/!][[W
MO=QOF0@"\<+1]T,FE=S^@0,':M_/[>B C;3V$?>SP./,EQ5!  !  $E$053"
M;8C0'BRWW'*!+&\)7GOMM4 4C7IW9YQQAK[+,@GFWN=XV_AQAA-NNNFF0)A)
MQ8.Q A)+E;[?C*7T#0B,Z(/0%5=<$8C'DF[3;T0!$M#N]-EB[91T?_05QF?Z
MI5@#]%WY_>]_K_U9%$;Z?%Q,E"9Z+<8#[EN42L%VVVT7B/)5WU6]H<B_:=.F
M!;P#U,O[+.YPP?777Q^((DC?"3]N1TXIN"F"7L#'J&LB4*AMF%/%LR[HUZ]?
M[N;Y+5;;8*^]]M)C)YUT4NZ8WQ A3,?KP8,'Z_O(NP0EC6^,E:)PU?['O"56
MX$"4G0%]][GGG@O$:T?/+?;>,F_'WW^QE@?P%?0W^HBGI/&S=^_> ?V&^5*4
MKKYHT;Z9*]A.&X7:1[P# E&2!N+5$(@A(1#A0.]"+,Z!"""Y,4ZL[CJF,S:!
MIRCV=7Z/S]711Q"F/,<O,/:+<48/)[5#=(P1Z[Z.$[0'Q#CJ>0'=(?_2KB\&
M$^7UQ#-,QZ"A0X<JG\><!L$W,K;"7S#VB054]W?FOT+MPWW!2T7GWJ0YESD>
MO)FK1% +Q&.RR2.)L*7]C><6SY7<<?%N"CP/S1QS^>67YXYU]XUB;0,^8B3,
MX4G;B$(O$*$Y$&-C\/.?_SPX[[SS\F#DW67NAV>%G^8=I6UX-V^YY18M"^_G
M^71XCDF3)FD?77;99?4XLH88/ )X8V09SA7EMQYC7!6#AVZ+9W- ?X*0K9B+
M1; .J(=^3]^"]^+ZU,78S/O&."O>Q<H;@X$H#W+\_=-//ZW7ID[ZD@CK;.:-
MM7&9A^-)SQ'E-2E3[@2_BWP)EC5=2?F %@8W5BRTN%")<.I$8%!KFC2XZ].G
MC]XNKHZXN'H7*VE(=;7&740F.+4D4O#))Y]4#0_U0%C=L51C&??$.;AGG7GF
MF:H5HDR4A/%5+;$,2*JU]]IT-)1HAR$L_-*I<J?A<H=FJ377Y1ZKJJI4HR7,
MJFKQN88(I[EKEO)\N9MJPPW:!A==;]58;+'%W-)++YUW!5S%:$\T=BQ;$*6&
M:LVPM HSE5>6'VC<T<+3_MXRS6\T>K@PXV6 FQS:0_!% R@=6S5],D!H&^ )
M@5:.)0>B6-'VGS]_OD,KCH69)11X(,C Y&A7&23R[@--'YI$KH]FT1-MB8N8
M#'Q.)B&_._?-.R'"C5XOM[.3-G"=9&T/[PG/07P%M)[T%;9I,Q&,U,N$OH5K
M)>\5UASO"2$#OEJDP96^AE6>8[1=$JYH0Z/M*A-!WM.C):5=>5_1YJ/)E\D@
MKPP:VW@[_N(7OW!X-43=V3F)?L>R@F>??58US+PG/+,H7YPP!TX4*CD+&_N7
M6&*)O&MUA1]8_AA3P)[V^>RSS]1=2R9BM;3AH8,'05+;L!^B+? :H"_B78#&
M&@\#VAI-.NZYN)M"C'LB$.@VFG7>=0CO U%PZOC'.K9"[<0UXO>'51_/)=H8
MBQKO'^\*&G ^]#'Z'?V;<4R$)">,HKXO]#%ANEUM;:U: X3YUG%";TS^H4UG
M'&1I#76P%(KQNIA;LS_?OBL'@9X]>^K[%;5 ,YZP7Q3SVL=YE['@13UHF(<8
M*QAWL*+3YR 1HG6\B8YO]#51 C@Q%FA_P4+/.QM=PL8V\T>A]S;M_<?JQ?O+
MMR?>_?CXR;S/.,;8C)<?EB7FT$)]T]?76=_")#MAPG7LQ;,1JQIS+_,QEB_&
M!<8XK-.B8'5_^M.?U+N1,1S^@3$^.E='GX.Y NLL<RQ6>)8SI;5#=(R!%\13
M4HPVZO7(N:(0C5:MVTG79T[AO>)]8@[B'<(;RK\_G,B\R)(;$:"41^%W.5'2
MG NN+%GC'8;OP8+*<T7['=N,]> 3)=J7_1#?C/E&+4. /H)%FO$-O.%_H^.0
MKQ6<X:WY,';YY9;P%!#\,WV"=Q=^601YY3>\'$,9YF$1MME4\C(02V^]K,3Q
MR<(70G@UPE=PC_!]U(7G#&,6]TI9[I4Q$KD*$J$Y9]'7'27\HU[&Y*C,4^@Y
M2JBR+(MT*2$=UVW<,WA)8.9@TA@@>5D8Q&EHB)>.@9\)  '93P3Q%L#%?="@
M0>H6R8"-2SPO<I18[RI6<)V4Q4JKZUSI&#"T".((-DP07 ^A(4ZX2R&T'G#
M 3H)<;REUXW7'?U-)^1^F.QP;Q$-2TG7B=;1%MM<GV=%P /;-&+RPA4&P0D%
MRR677))6M.  0OO M/ .4!<3 X, $P(" H( 0CC$!,I[@CLQY7$CXN/=?1A8
MF% 92!A<XL0$SJ# 0.85(# 37)-SF.1A! GD@9"/2SR$ZS)KHUEKV-G$^XJ
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MZ\?%O5+;1Q1?P=.R7D@&4UU#SMI(<(Z?YW&-MZO?3XP"UEN+ !F DTP4&I]
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MT+70K,$F* C1A"&Q6NG:%X(6D6./R-V>6%LLVD\5QOP^^^[>"+ .D<!:1H:
M(6 (& *&@"%0V0B@M"5S24L)Q:98EUMZ>MF=9X)?V359E[]A@AG[F$BEW*RD
M@-,U[JR?9]L3,AT9ECS)DA-5OL77[Q-###FQ4JA+">D$12(X",%'"/:!Q89
M"J>??KI&IB9('(&\B!Q*T#9QU7&R#E,#J)%V9;)82M'D$76;X&8(\4:&@"%@
M"!@"AH A8 @8 H: (6 (& (=AP#99IHCI%]XX84:H)E GE$B_3$>.+XNLA#@
MK82GBR=2:T:CQOO]Y?Q=U95N'NT';L@(Z6A)B/H-H0DE:K,$?]'HGD3QADCU
M053OW7??7=V1B-(.$8V3"/!&'8, [5).1"<F][HG!I&WWW[;_RSZS7M)#NIR
M(J)PDS,80K/IB0&1_A*GYF!"5%+RRQ-!])!##M&TB='Z\%[PWB_L)V4B4<N)
M]$DZC\XFE'X=,;"3(HIG)F,$&$"DF22BN_^ 2Y1(7Q9]-VDOTMEYPLN(28KL
M Q)DT>_62,9$C.4])6U@1Q+1^TE]1(1G(N]#>$7Y9^2;Y_ $%NSS1%1AHL5&
MB<C,\>>1E6CNHHLNTF?G>K+>/GJ*;5<@ M&Q1-8BY[U3O$,2#$N?&B\ZH@23
M6>3<<\_M\D@T9[SM\@^3<H-DA\']'(K.1RG%N_QNTM'B_>FIW/@@?]_VW;D(
M,(XAWQ ='^LQ\SM1TD>/'JW&2-(=0XQ]\%ADK$" E?@(FK&(]PX/9.C**Z_4
M91FD+J:<EZ'(E$*T?;(A$3'=ET7F(N.+C\S/W$U9#* 08Z?/G*4[Y!_'N#;U
M<3[] ,+ *D$P=9M(\S?>>*/R-Q*;0^O$V!HE4N0>*MD:N#Z"-Q[4-]QP@Y,@
MNQI!WO.KT7/PC $CC+0\-]F^V.;#LCCN/\I+1,\MU^TN):1[$'EIL9K[O,JD
M%$)K O$='1C9=]555^E+1JHIB#5*S5D/IB?9OQ8C0"<L)Y(H[YH.PM\SWAEQ
MK9T_EO0MP5'*3B @91SN_A ,H2>86=(3QJDYF##8,E@SL1 ;0"+(YZJ;.G6J
M>K;X-$BL\:-NTO4P69"FQRO7<B=U\ :"+@)?>Q+/2/I"%"0(Z7P@A&N$;#X(
MH:3X\P1V3#I,AO0Q)E+:3@+F^2)Y7D;@3PH<QD^$?8E0K!,V^84[BB3(FTZ8
MW"O/RH0*D=;2/R=C.!.QI^NOOUXG>'Y+U'I=9Q=U,4U['IA^R;:@<P7O,/F0
MC2H7@?A8XJTH_KW"$\\KVUB##-/'.T'*H*Y.S1EON_JSI-T?RF"?_C,Z'Z65
M[^K[,1Z1'M-3N?%!_K[MNW,10-8A%L#8L6/5>(3@"0]%"F",2:0<@V^28(OZ
MD2!T[N&''];YE?D/)3X>Q? P$@C3C1PYTI$N%V]DKPS'59RZ$.;A"R#*(C-A
M9.%ZW >_2;.&LA/>D#Z+82%*S,VDR^:#\46R&^EA>!SN$R(7._T!3VB$9](6
MHS2-$@8*[I5ES/ $I*V$;V%<IWS<$,9^^"/2+Y("VBL$?)VDK$41$(^-XX^7
MZW>7$])A0&%682S)DPZQ+DBB;.HV+P%!5CS1L#"#6*F,VA<!K*6T#0(M'@^>
M(:(S(Z1)>B;ME-P%[4$'A%F7-$NY'+7\IF/C+4$NQ6*:098P4 ^=4E(Z:0P"
MZI>4;!JW "T<@A[$X,/D3VP"\D?RSF E]82&C0&! 8T\GF@,N0>4/%Y01'.(
M!I+[8P!,>PY?9U?YQF+IK=4L\_ ""\],SFP8"@9W!D8&3Y[=:S;)61G5IO),
M'A,TLW%M:_R9\7IA0"7P'[DS?0! +)LPGWZBX#PF$J[/-P%F4*@AA$5)4F_I
M_2'@L48.094RI6J;R8W+=5%*<![! FE3)AOJ@IA\N#[O(TJ;]B;>8YX9!0]"
M-^.<1'1VD@XPIPEF8D1#[0E--)X)D)^@Z$M12O(RHIUI$[!#4YWT?$S@7D./
MD@*LR%V\]]Y[:S_#0RGJ;>*OF:21]\?XYIZQ $C*-+UGXH5 DM)'GY-O%#:^
MSTHD?GTO:3/HR"./=#?==)-N^W]IS\.SH^Q HXZ@YCVL_'GV73D()(TE:584
MF$>40#!M,&STL3@EC2>20DIS^#(FD.,7*L5Z11GR:4MZ+GT7__G/?^JYDN)3
MYQ&L5T<<<83V_[3QU(^WG!B?QYA?B_5+O6 G_HO.ZY+>KLF<C;<,^!([2-)-
MYN8C;GG--==LPC\P3C)V,9<P9GA>,/J(:7-S? X'<ZX+K\$<DM3.21CCO0//
M >]!;N<HP5N0]YFZ&1-1/B3Q06GS3[2NCMB.8Y*$ ?=!6^!]0KYJ\&?IJ*15
MRRE1F_.N^[[#W$(P.F^1W6*++7("%GP:;=.=B?D0CSF"^('[A D3M!T(:@E_
MQ/@%EA#] 4,(/#C?S*_$[<*Z[05DL*8N> 4LZ2C.F8_Q9J/=HQYG\-;(4[0Q
M2DX(KS3X1]:#8T2(!^-%,24I?36()=^2QC!G>=<*2OQ'/=P7Q'=4X954!6,H
M.*"40 E+W_.$X@ ^!QFEXD@8QRY#(D!ISM_;;KLM[Y[([R@OLNX3ACNXY))+
M-$61"!F:_SDI'^-YYYT7R&275X_]*(Z "'BIA<AO+8R]IHL1#5D@+BU:5@8)
MS7M.&AD10#3-F3#^F@J+]"4BY&GZ$@K+FA+-N2V"6B#,M^;3)'V::!$#&0PT
M#RKIPF0PTC:6@4?31I&2@/:6V ,!Z5O(W4W.5!F< NFX@5@0 W&WT6/2B0,1
MU#4ME0ABN>>102L0!D[+BK(AMY\\NM0A@KOF;99!3*\IPJWFH"2E5_0YR'5+
MSM3.H+3V$86)YB@%#W)FD\^5="C++;><?I,K5ER#]99]'GI^B'8S$*NVMJFX
MGFMJ.O9[3-*.4R9*M)DH:;1=R/O+NR 33R "5T#*+A&D<L7%+5MSK(I+5B!"
M:&Z_W^":O%\0;<R[<LXYYP3"=&M[D_N=:\C$HBG=A!'2ZY*&3 ;K0"8>;6?.
M$^8DD E'WP5AA /P$X$YD,DO$,N<7D,4%$%;Y51/:Q\N),MR M$8!S(1!^+N
MJ=?V_WC_N&]2_D"THPC*3=+,D;N>G,.>R!GNT]K1-X6QTGXIP51\$:V'9X[2
M$T\\$0ASJ;O(-\RX"G;";&O.5=YY<AW'B71HDR9-"B3FASY'_#CM2;N(DD1S
MPM.642*_._?H200:S4/L?_,MC(3FI_;[&&>2GD<4A;G42N1MY?TK1(PW?(RZ
M)@)I;5-H+/%/(H)?+J>S*.X#QCAR"(L;9 #_X/N5+Q\?3^C_S!GT+<8183X#
M87"U3XB"3U-\ILU1]!L11 +&0/J9,,[:?QE_>"]YG^GSLNRDZ'B;-(^5TB_]
M<[7G=UK[<,WHO,[\S!P:G;,I(]'1 Q'6V=3<Y7X^2N(?:$-1-.I\3MOX_/9Z
M\J)_23Q&TAS.&"0*VH!Y@W/2VCD^]L'O>%Y4UL-&+ZW;S"WD2/>4]!Q)\X\O
MW];?:>V3A$D2!MP/S\#<"M\%[R2"D]ZF"-8ZIS;G7:<L? C]@+1L(CQJ7;),
M-1 EL6[#1WG>7G=4Z+^TMN%QF<=\7_!C"/P2;2"*'^5MZ$_@R9@&D7Y6A'?=
MYA]\!65YUY&/('@,QC&QNBL_QS[.@V> HF49Z^B?$.,M=3-FB=>R[HO^$ZN\
M\MKL$\6X\LQL,P8_\\PS; ;'''-,<-EEE^DV]\:8&B?Q"@S@R2 QY 2B&-7M
M*'^J.Q;]B_(CH@ -9/UY[K 8!@)1JN5^E_L&8R?/RYA5U96T#JRIE %"+7QH
M>+!^0<+X.B+X825%(XN&#RNNO&2J/<%R0WFOP4:;@J4,=UK*&K4= BNOO+)J
MWM!*^_4N6#30]J&1$Z'0X?[,6F,L"[0!Z4N\]@Y7&JSQ6 8)\E=,,X@+$!9!
M8:I4PT@]:.K1^*)%1&/(=7#G82T/2R1POXEK_TI! (TF6F0\-_A@34Q[CE+J
MZ\@R/"^:5];Q8-49.'"@;M.'P+D0T7?BVM1H^6+'*2N3NQ,&5=<PX>+TVFNO
MJ>LU[M>X:&-1((8$%F291+0LEA \&N(:5*)SXJXE0I<[\\PS56/;'&TS7@%8
M0'C'>"\((HE% ,LK6.#>A7;?+W&(>N9$G[LMM[W[&!X;:(#Q>J!?>,*E#7Q(
ML03)9*=6?IE0?9'$[R0O(_H8EAY/:-CCS\AZ<=H"K31N;G@;X$:&10S<P0L7
M\B@5TLC[<IR#YP1>*+BLB;)4+8@<YWS<V1FW/;$&+;X.WQ_SWVG/$W_V8N^Y
MK\^^RPN!M+'$/X4PKWE6%-Y!QA#&#-Y!O&?\NDE_3GP\8>S$ @^/P7PF"MW<
MN%1LCJ).W#49 ^D[N*["QV"Y(EX.<PCOII\#"XVG2?-8L7[IGZDSOZ/S.IY;
M\3F[T+TE\0]XO&%=(U!46K].FIN3YG"N#;^"E9+Q-:F=DS!FWF),QJN.=BE&
M2<^1-/\4JZ>MC\<QP=*:A '7Y1GP3,(C#IX"+Q"(N9)EIU!SWG7.8Q[&:PT7
M: C^@"C=W /M[+VH]& W_$?\%?AD^@Q>&Z+4T.6 \+7P*7CD,-?!Z_*!HMOQ
MW^>??[[R/P11(V8+[S[R$IZ)\+<BP#:I(UH?O (>:O#T?KF:GK#H']9U/)0X
MQK)%[^Y^J,A:?.";\9#PQ%(W^-!XG# LXWC$\MRXL7,NY)]1?T3^X66(_ $N
MHO10F9##\)&\KY7Z'G6IZ.Z\J'SBA!!.\",8?3J[)_^R^=_^.^XNZ??;=]L@
M .YT0H)3I!%+$&#^<07#?::E1 >DD]-!Z="LNV7@AW'#59;!2[1-RE2)A2_G
M*@MCQH1,A_?"!D("A)N0:"R;W!+U(C#Z]PKWG[9ZCB87:X<=N 0R$(KV7YE6
M!+_H^G!_2098!#<FY+8@7/U@@&"FJ)NU4RA1/&/#VB?65^&"S@2$:Q;MQH2$
MZS?G1XEZQ-*K3"V3"DPX;8-;%9,6S"[O'L(VPBCUX2+&I,%[$268;=99^8B@
MO!?<(TH W@O:VC//T?/:>IOUL;QW3( L'X#YY!V$@6&I B[G!%[Q5(KP2EF$
M:A0AN'^A\ !/]J&DY-F8G%$&>+=S7S_?HNW6299[H+THBTLB]X8[.G5$@]&A
ME*,L2@\8+N^^&*T3Y0CM1%NCK&/"]I,N+I<HT5#D0;09[0<37(C2GL<_.[CY
M9R]4CQTK3P32QA+_- A3O%M>$<4[R+(>Q@4^]"T8SBC%QQ/&0P02QA3>699.
MQ)G*Z/EIVXQE"#,HUQ B&>\@E&ZE$.-5?!ZCCD+]LI1Z.[),TIS-]=/FW:1[
M0]',^,,8)5YL2442Y^:D.3QZ,F-;4CLG88QK/ H'%*N\@PB7*&(\\3P^$)[?
M%_].FG_B9=K[=QP3E+-)&#3W/IK[KOMY  ,"\SK+'NACOM\V]_J54I[YCR5^
MM O*0O@?>"/X9K#Q?!I]@@\DUF8]QV/@7=7YS=R-D,U:<(\YQB[*>,,6Y;QP
MS39**A_DE=_P%"@9DPB!&!D+O@)^P!-+8/VR$/@[3R@-N!:*O"@A<,-OT_>X
M5T_@D$1<$QZ>L3IJA(/7X%.IU*6$]$(@\^)&!?1"9>U8^R% $!X8']H"+1WD
M!P*_S6\&":P9=#Z$:9_+,*EL]#RV(<KQ@0&G\S/QLTX-*P3,.?5CM>##;X0:
MA'AQX]+! R8)04_<;_4X XO7Y#+A\@RL5^>^_+58&T4P*A@Z!D8FD*3G\.7#
M.^TZ_[$\H*%FS1>,*DP%6D\H>L]>LTEY)@6.Q<OX\OX[?EQ/6/0/9I0U3 A?
M,#3< X,T&E((Y1K,D1?&\'3!8L5$P_6YGRBQ5AHF>_CPX5H/ZYYH9P11E#1,
M#L020(N+5I5[3-(V4R=KG+%:L[X*90Y"(I9<M*Y,$KR?7GD3O8>VWN:Z6)=A
MVGCWL%QCH4.09E)%&/;MP*2%D'"CK._VQ#X\4! B:%>4#KR[>!D1#P"+-0(O
M6GEP!6N4%F"%%XJWT/OZ^*9O$,S.7P=/%&(8H !A?2416J.$1A[%#_6BZ/#*
MK&@9UH:S'I[V93)%>(((^H6G$_?OB7@B<2LZ7A;<#\H4%'PH=U#,)#T/_95W
MF'(H!,#7J/(0*#26)%E1&-=1[,/H\M[33UC;&27Z27P\H2\Q-HF[IZZ#9AQ%
M^>/[970LI*[H;Y36C$58T.DW]$'F2N8:YAZ$.5\^J3Y_C+$N/H]Q7X7Z9?2Y
M.FO;/Q/73YJSV<\8B-"-0A=/'G^._Z:,QX%Y"\4&8PU*$[P3XI0T-R?-X;Y.
M?WY2.\L2MB88\]XPGR&,,TY%!73J8CQ&V"2(%_-+TG.DS3_^7CKB.PF3) RX
MEZ1G\/O]L9:\Z[X.OB'F+V+AT(9&(0+Q,0J>J;F$EP/C)7Q5G. W2B'&*N9N
MQL="%!70?;FH<.[W\4T?2J.H@)Y6QN]/>BY_K&*_A=$R,@1R",C@G=N.;[!&
MB[6S(M3$#R7^%L%"U_(E'FS&3K%XZMJ^^"FLP8G?BP@JN36ZOCPQ"UB?'2>_
MEC>^G_MF79VGMGH.7U]KO@NU3W/J%>&MR3K-YIP?+PM>K/%F/5,I1)N":QI1
M7])QUI]'VY)RU%6,6.O%.NLHT?[1NJ+'6KI=K'UX7V4"+%B]>!,%Q>J)5L S
ML.8O3J*1SGN/X\>3?E,7&!<B85QUS6VA,F*5+W18<1=KCJX1+5@P<C#M>7CV
M4MX[U@7R,>J:"+1UVS#N%QL;XN.)*-":/6?YM:*L=X[W;=:D%[N'I-:(SV.E
M],ND>MIR7W/:AV?FV>/$>!T?A^-E^,WS$P>&.5Z\V0+QI$LJIG,$<UF<XG-X
M_'A2.R=AS'C-/:01XTZ<!TDJFS3_))5KS;YB[1/') F#8M=OJW>=-<BB!"EV
MN8HY7JQM*N9![4':!('HFO2RL:17K):DC!X,RR,:[5(U7TF:MI8\+E9M7*3B
MA#6/3Y2PG,2U;5@UDBA>SI>)WW?\MR]7SM^%-)LM>2ZTOKC5E4JTJ7?C2CJ'
M^I(TR2W5-L>M(%PSK?V3[J>M]I72=[ >X3U2*J5Y&15;SYY4/W7%,8Z7*T4C
M'W5'BY_/;V'6=6E3DH4LJ3S[TI['/*S2$.O>^]/&_2@J\7<=:V%SQT;>8=;Y
M)KW+2?-6]/IIV_%YK)1^F5979^Q/F[.3QO2D^\.2AU<.GD 2T"K5]39M;D[;
M[Z^5U,Y)&!<;KW%'+E:&:R;-/_Y>.NH[CDD2!L7NI:W>=3P7B$]B9 @8 H41
M,"&],#YV-(( +LA&AH AT+X(X*I;Z02SA^N_D2%0[@BPK,<O[2GW9^DJ]X_;
M++%(C+H6 FWUKA/7Q,@0, 2*(U!5O(B5, 0, 4/ $# $# %#P! P! P!0\ 0
M, 0,@8Y P(3TCD#9KM'F"! D2W*?MGF]5F';("#Y-34B?TMKDQR?FD*NE/.)
M2G[__??GBA+P9-RX<;G?ME$< =+A8,%G28LLJBI^0J2$X1\!PS;;!0$BN),N
ML!0BW1KCCZ<5):542Z@YU\0R2(#*YA!!2@G25 E$!&?<T@D(1Q#74LEC3.8(
M F!">^ZYIZ;G*K6.0N4(6$G0O>B' )D$[^0^B0I-E'&RQ^!:#Y$-@-2?!!<E
M$P?;/OU8H6O9,4.@)0@4>A=;4E\IY_A^5TK9MB[36MZPK>^GJ]=G[NY=O87L
M_A(18/W8L<<>FWC,=G8^ J0]@]EJ*1$=O-34+*0LNN:::W)Y,DFI)D& 6GKI
M;GD>D=>)9DQ&AN:2X=]<Q*Q\<Q% F"HUYL6CCSZJ:8R\"[H$S&KNY;1\<ZZ)
MTI@X"\TA4HR1$JE8_(;FU-E99<D&0;87QETBU".LDYVC&'F,R?K@4V&2FI((
M^VU!$M3-2;!;1R8)3V!.=A#VD56#:[&4CTCNK!TGJC_S#VNF)0">QLX@G6@\
M$X6OS[X-@=8@D/8NQF,(M.8:\7-]OXOO[XC?K>4-.^(>N](US)+>E5JCB]\+
MUC;2JY 292M)=0:1$@L+W":;;.)(G05=>>65FIZ$7)P$U"$%%/F;5UMM-4VI
MY,N@>2?=TZA1HQR:=(AT2I3E7(ERK?M(B[/[[KMK73  I%)#@#OEE%/T."F^
M2&E%/5C72=\$T[#WWGMK*C+N-VIIU9,J\!^I>\ 'G$GKA886"P%X8A' P@2!
M)]8#F"CP!D?2SM&&8.?+D&(&QI@@9EA+)T^>K"GP2&U$BC?2$T&D&:)^TJ21
M'@PBAZJ/8<![PZ2PP08;:-HT[HN\H%R;(&DPT_ZZ>K+\@]&6B*C*8)'ZBS1<
MO$M)N;DOO_QRO1?J8\*#2"U&>?^^L(^4+Z3V(2?H55==Q:X.HR3LP(B\I]YR
M?<$%%RAF2>\S-TJJ0:QUI"-[^NFG$]N"5'@PH92E'/G9H;///EL93_HM*72B
MA&8;(9UT:;PW+[WTDN8[I8XSSCA#B\+H8EFB'6F+*)4#_M'[M>WR0X#^BA#%
M>UAH/$!81F''',1X0!]C+HB/3R!0J$]PO-@U2?M'?R+U))8IB.N3 LX3%MSW
MWW^_R7AWWWWW:3\C/19C<;Q_D?[SMMMNTVH0-)ECJ;NKDF2CT#&'8'T$AXL'
MY>3Y&.M(4X=G ^,-Y#%.>JZD,9-RT7&0/,N%YA'*$_\"H=M_$'Z86XB) <\
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MG AX[[OOO@A^\W)JT@E:F7.\.D@?-&A06GGEE=/<N7/3G7?>&37V!.L///!
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M? 3GU*13II;F<-UJJZVBMI]C<<. 1#_^"RZX(#W]]--I^/#AZ=QSSXWE_E)
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M+8'>2^M 'D<!!110X.,"W&4W*:"  @HHH( ""BB0!0S2LX2/"BB@@ (***"
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M"BB@@ (***"  @HH8)#N>T !!1100 $%%%!  0444$"!!A$P2&^0"V$Q%%!
M 0444$ !!1100 $%%#!(]SV@@ (***"  @HHH( ""BB@0(,(&*0WR(6P& HH
MH( ""BB@@ (***"  @H8I/L>4$ !!1100 $%%%!  0444*!!! S2&^1"6 P%
M%%!  0444$ !!1100 $%#-)]#RB@@ (***"  @HHH( ""BC0( (&Z0UR(2R&
M @HHH( ""BB@@ (***"  @;IO@<44$ !!1100 $%%%!  044:! !@_0&N1 6
M0P$%%%!  0444$ !!1100 &#=-\#"BB@@ (***"  @HHH( ""C2(@$%Z@UP(
MBZ&  @HHH( ""BB@@ (***" 0;KO 0444$ !!1100 $%%%!  04:1, @O4$N
MA,500 $%%%!  0444$ !!110P"#=]X ""BB@@ (***"  @HHH( "#2)@D-X@
M%\)B**"  @HHH( ""BB@@ (**&"0[GM  0444$ !!1100 $%%%! @081,$AO
MD MA,1100 $%%%!  0444$ !!10P2/<]H( ""BB@@ (***"  @HHH$"#"!BD
M-\B%L!@***"  @HHH( ""BB@@ (*&*3['E!  0444$ !!1100 $%%%"@000,
MTAOD0E@,!1100 $%%%!  0444$ !!0S2?0\HH( ""BB@@ (***"  @HHT" "
M!ND-<B$LA@(***"  @HHH( ""BB@@ (&Z;X'%%!  0444$ !!1100 $%%&@0
M 8/T!KD0%D,!!1100 $%%%!  0444$ !@W3? PHHH( ""BB@@ (***"  @HT
MB$"OIB(U2%DLA@(*M"%PVVVWI7'CQK6QE:OK)>#UJ9>\QU5 @24IX/^V):EK
MW@HHH,#?!&;/GIWZ].F3>O?NG0S2?5<HH( ""BB@@ (***"  @HH4$>!<I!N
M<_<Z7@@/K8 ""BB@@ (***"  @HHH$!9P""]K.%S!1100 $%%%!  0444$ !
M!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]K.%S!1100 $%%%!  044
M4$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]K.%S!1100 $%%%!
M 0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]K.%S!1100 $%
M%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]K.%S!110
M0 $%%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]K.%S
M!1100 $%%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9P""]
MK.%S!1100 $%%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HHH$!9
MP""]K.%S!1100 $%%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"  @HH
MH$!9P""]K.%S!1100 $%%%!  0444$ !!>HH8)!>1WP/K8 ""BB@@ (***"
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MW'-60 $%%%!  0444$ !!110H!$$9L^>G?KTZ9-Z]^Z=&J:Y>R/ 6 8%%%!
M 0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HHH( ""BB@0$G (+V$X5,%
M%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HHH( ""BB@0$G (+V$
MX5,%%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HHH( ""BB@0$G
M(+V$X5,%%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HHH( ""BB@
M0$G (+V$X5,%%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HHH( "
M"BB@0$G (+V$X5,%%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"  @HH
MH( ""BB@0$G (+V$X5,%%%!  0444$ !!1100 $%ZBE@D%Y/?8^M@ (***"
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M%%@, 8/TQ<!S5P444$ !!1100 $%%%!  04Z4\ @O3,US4L!!1100 $%%%!
> 0444$"!Q1#X?X&MW;(N&IFA     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image.jpg
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J=PU<#\/^4J5*E2I5JE2I4J7FMIS['Q-1/-?G =S"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
